Nursing management of gynaecomastia encompasses assessment, care planning, patient education, and coordinated referral for males presenting with benign glandular breast tissue enlargement. Although often physiological and self-limiting, gynaecomastia can cause significant psychological distress and may occasionally signal serious underlying pathology, including testicular tumours or male breast carcinoma. Nurses are pivotal in distinguishing true gynaecomastia from pseudogynaecomastia, identifying red flag features, supporting patients through investigation and treatment, and facilitating timely referral in line with NICE NG12 and local UK clinical protocols.

Understanding Gynaecomastia: Causes and Clinical Presentation

Gynaecomastia results from an oestrogen–androgen imbalance causing glandular breast tissue proliferation in males; causes range from physiological (puberty, ageing) to pathological (hypogonadism, tumours) and drug-induced (spironolactone, antiandrogens).

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia refers to the benign proliferation of glandular breast tissue in males, resulting in visible or palpable enlargement of one or both breasts. It is distinct from pseudogynaecomastia, which involves fatty tissue deposition without true glandular growth and is commonly seen in obesity. Understanding the underlying aetiology is essential for effective nursing management of gynaecomastia and appropriate clinical decision-making.

The condition arises from an imbalance between oestrogen and androgen activity at the breast tissue level. Common physiological causes include:

• Neonatal gynaecomastia — due to transplacental oestrogen transfer

• Pubertal gynaecomastia — affecting a substantial proportion of adolescent males (estimates vary; NHS.uk notes it is very common in this age group), typically self-limiting within one to two years

• Age-related gynaecomastia — associated with declining testosterone levels in older men

Pathological causes are equally important to recognise and include:

• Hypogonadism, including Klinefelter syndrome (47,XXY), which also confers an increased risk of male breast cancer

• Hyperprolactinaemia (e.g., due to a prolactinoma or pituitary adenoma)

• hCG-secreting tumours, such as testicular germ-cell tumours, which stimulate oestrogen production

• Hyperthyroidism, chronic liver disease, renal failure, and adrenal tumours

A thorough medication review is critical, as numerous drugs are implicated. Those with stronger evidence of association include spironolactone, antiandrogens (such as bicalutamide and flutamide), 5-alpha-reductase inhibitors (finasteride and dutasteride), ketoconazole, digoxin, and some antipsychotics (particularly risperidone, which raises prolactin). Anabolic steroids and exogenous oestrogens are also well-recognised causes. Nurses should note that cimetidine, whilst historically cited, is now rarely used in UK clinical practice.

Clinically, patients typically present with unilateral or bilateral breast enlargement, tenderness, or a rubbery subareolar mass. Asymmetry is common. Red flag features warranting urgent investigation include hard, irregular, or fixed masses; blood-stained nipple discharge; skin or nipple retraction or ulceration; and associated axillary lymphadenopathy. These features may indicate male breast carcinoma, which — whilst rare — must be excluded promptly. Risk factors for male breast cancer include older age, BRCA2 pathogenic variants, and Klinefelter syndrome. Nurses should be familiar with these presentations to facilitate timely triage and referral in line with NICE NG12.

Assessment and Nursing Evaluation of Gynaecomastia

Nursing assessment requires a detailed history including medication review, physical examination to differentiate glandular from fatty tissue, and baseline investigations such as testosterone, LH, FSH, β-hCG, and prolactin guided by clinical findings.

A structured and systematic nursing assessment forms the cornerstone of effective care for patients presenting with gynaecomastia. The initial evaluation should encompass a detailed history, physical examination findings, and a holistic appraisal of the patient's physical and psychological wellbeing.

During history-taking, nurses should document:

• Onset and duration of breast enlargement

• Associated symptoms such as pain, tenderness, or nipple discharge (noting whether discharge is blood-stained)

• Full medication history, including recreational drugs, anabolic steroids, and over-the-counter preparations

• Past medical history — particularly liver, renal, thyroid, or endocrine conditions

• Symptoms suggestive of hypogonadism (reduced libido, erectile dysfunction, fatigue) or thyrotoxicosis (weight loss, palpitations, heat intolerance)

• Recent unexplained weight change and testicular symptoms

• Family history of breast cancer or endocrine disorders

• Alcohol use, as heavy alcohol consumption and chronic liver disease can impair oestrogen clearance and disrupt the hypothalamic–pituitary–gonadal axis, contributing to oestrogen excess

Physical assessment should involve careful palpation of the breast tissue to differentiate true glandular tissue from fatty deposits. Nurses should note the size, consistency, and symmetry of any mass, and assess for axillary lymphadenopathy. Testicular examination findings, if available from medical review, are clinically relevant, as testicular tumours can drive oestrogen or hCG excess.

Baseline investigations are guided by clinical findings and local protocols. These may include early-morning total testosterone (repeated if low to confirm), luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, beta-human chorionic gonadotrophin (β-hCG), prolactin, thyroid function tests, liver function tests, and renal function. Sex hormone-binding globulin (SHBG) may also be measured where indicated. Testicular ultrasound should be arranged urgently if a testicular mass is suspected or β-hCG is elevated. Nurses should be aware that the scope for directly requesting investigations varies according to local governance and protocols.

Where malignancy is suspected on the basis of red flag features, patients should be referred urgently via the two-week-wait breast clinic pathway in accordance with NICE NG12. Imaging and biopsy (triple assessment) are arranged by the specialist breast team, not independently by nursing staff outside agreed local protocols. Nurses play a pivotal role in coordinating investigations, ensuring results are communicated promptly, and supporting patients through what can be an anxiety-provoking diagnostic process.

Nursing Interventions and Care Planning

Nursing interventions include liaising with prescribers about causative medications, advising on compression garments and analgesia for discomfort, lifestyle modification, skin care, and producing an individualised, documented care plan.

Effective nursing management of gynaecomastia requires an individualised, patient-centred care plan that addresses both the physical and emotional dimensions of the condition. Nursing interventions should be evidence-based, proportionate to the severity of the condition, and aligned with the patient's expressed needs and preferences.

Where a causative medication has been identified, nurses should liaise with the prescribing clinician to discuss potential dose reduction or substitution. It is essential that nurses do not advise patients to discontinue prescribed medications independently, particularly where these are managing serious conditions such as prostate cancer or heart failure. Clear communication within the multidisciplinary team is vital.

Practical nursing interventions include:

• Pain management — recommending well-fitting compression vests or sports tops to reduce discomfort and chafing; simple analgesia such as paracetamol may be appropriate for breast tenderness, and NSAIDs considered if not contraindicated; persistent or severe pain should be reviewed by the clinical team

• Lifestyle advice — encouraging reduction in alcohol intake and avoidance of anabolic steroids or recreational drugs that may exacerbate the condition

• Weight management support — in cases where obesity is a contributing factor, referral to dietetic services or weight management programmes may be appropriate; nurses should clarify that whilst weight loss benefits overall health and may improve pseudogynaecomastia, established glandular breast tissue may persist regardless of weight change

• Skin care — advising on hygiene and skin integrity beneath enlarged breast tissue to prevent intertrigo

Care planning should incorporate clear documentation of assessment findings, agreed goals, and planned review dates. Nurses should ensure that patients understand their care plan and feel empowered to raise concerns. Where gynaecomastia is secondary to an underlying condition, nursing care should also address the management of that primary diagnosis, ensuring a holistic approach that does not treat the breast enlargement in isolation.

Medical and Surgical Treatment Options in the UK

No drug is licensed specifically for gynaecomastia in the UK; tamoxifen is the most studied off-label option, initiated by a specialist, while NHS surgery requires demonstrable psychological impact and is subject to local ICB commissioning criteria.

In the UK, the management of gynaecomastia is guided by the underlying cause, duration of the condition, and the degree of patient distress or functional impairment. Nurses should have a working knowledge of available treatment options to support informed patient decision-making and facilitate appropriate referrals.

Watchful waiting is the recommended approach for physiological gynaecomastia, particularly in adolescents, where spontaneous resolution within one to two years is common. Regular reassurance and monitoring are key nursing responsibilities during this period.

For persistent or symptomatic cases, pharmacological options may be considered by a specialist. It is important to note that no drug is currently licensed specifically for gynaecomastia in the UK; all pharmacological treatments are used off-label and should be initiated by an appropriate specialist (such as an endocrinologist or breast surgeon) with informed consent clearly documented. Treatments used off-label include:

• Tamoxifen (a selective oestrogen receptor modulator, SERM) — the most studied option; evidence suggests it can reduce breast volume and tenderness, particularly in early or active disease. Patients should be made aware of potential side effects and advised to report any suspected adverse reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)

• Raloxifene — an alternative SERM; evidence is more limited than for tamoxifen, and any preference over tamoxifen should be determined by the specialist on an individual basis

• Aromatase inhibitors (e.g., anastrozole) — used in specific cases where elevated oestrogen is confirmed; evidence of benefit is limited in many presentations, and potential adverse effects including bone mineral density loss mean that specialist assessment and monitoring are essential

Patients should be counselled that pharmacological treatment is most effective in the early, proliferative phase; fibrotic, long-standing gynaecomastia responds poorly to medication.

In patients receiving antiandrogen therapy (e.g., for prostate cancer), specialist teams may consider tamoxifen or prophylactic low-dose breast-bud radiotherapy to prevent or manage gynaecomastia; nurses should be aware of these options when supporting patients in oncology or urology settings.

Surgical intervention — typically subcutaneous mastectomy or liposuction-assisted surgery — may be considered for cases causing significant psychological distress or where conservative measures have failed. In the NHS, access to surgery for gynaecomastia is subject to local Integrated Care Board (ICB) commissioning policies and is not routinely funded unless there is demonstrable psychological impact. Nurses should help patients navigate referral pathways, advise them to check local ICB eligibility criteria, and set realistic expectations regarding NHS funding.

Psychological Support and Patient Education

Gynaecomastia frequently causes embarrassment, reduced self-esteem, and anxiety, particularly in adolescents; nurses should screen for depression and anxiety using validated tools and refer to psychological services or CAMHS where indicated.

The psychological impact of gynaecomastia is frequently underestimated in clinical practice. Many patients, particularly adolescents and young men, experience significant embarrassment, reduced self-esteem, social withdrawal, and anxiety related to their appearance. Addressing these psychosocial dimensions is an integral component of the nursing management of gynaecomastia.

Nurses are well-positioned to create a non-judgemental, confidential environment in which patients feel comfortable discussing their concerns. Active listening, empathic communication, and validation of the patient's experience are foundational to building therapeutic rapport. Screening for anxiety and depression using validated tools is appropriate; for adults, the PHQ-9 and GAD-7 are widely used, whilst for adolescents, age-appropriate tools (such as the PHQ-A) or referral to specialist CAMHS services should be considered. Onward referral to psychological services or counselling should be arranged where indicated.

Nurses should also be alert to the possibility of body dysmorphic disorder (BDD), particularly in young men who express distress disproportionate to the clinical findings or who repeatedly seek reassurance or surgical intervention. Where BDD is suspected, referral to appropriate psychological or psychiatric services is recommended in line with NICE guidance on OCD and BDD.

Patient education should be clear, accurate, and tailored to the individual's level of health literacy. Key educational messages include:

• Reassurance that gynaecomastia is common and, in many cases, self-limiting

• Explanation of the condition — distinguishing it from breast cancer and addressing common misconceptions

• Information on treatment options and realistic timelines for improvement

• Guidance on lifestyle modifications that may support resolution

• Signposting to reputable resources such as NHS.uk, NHS Every Mind Matters, and the Men's Health Forum

For adolescents, involving parents or guardians (with the young person's consent) in educational discussions can be beneficial. Nurses should also be mindful of the potential for body image concerns to intersect with disordered eating or excessive exercise behaviours, particularly in young men, and address these sensitively. Continuity of care and a consistent nursing contact can significantly improve patient confidence and engagement throughout the management journey.

Monitoring, Follow-Up and Referral Pathways

Follow-up every three to six months is recommended for conservatively managed patients; urgent two-week-wait referral under NICE NG12 is required if red flag features develop, and non-responders after three to six months should be referred to an endocrinologist or breast surgeon.

Ongoing monitoring and structured follow-up are essential to ensure that gynaecomastia is resolving as expected, that any underlying cause is being appropriately managed, and that the patient's psychological wellbeing is supported over time. Nurses play a central role in coordinating this follow-up and recognising when escalation is required.

For patients managed conservatively, follow-up appointments should be scheduled at regular intervals — typically every three to six months — to reassess breast tissue size, symptom burden, and psychological impact. Pubertal cases may require observation for up to one to two years before intervention is considered, unless red flag features or significant distress are present. At each review, nurses should:

• Reassess medication lists for newly introduced causative agents

• Monitor for red flag features that may indicate malignancy or disease progression, including blood-stained nipple discharge, skin or nipple changes, or a new hard or irregular mass

• Evaluate psychological wellbeing and adjust support as needed

• Document changes in breast tissue size objectively — consistent tape measurement or clinical photography (with documented patient consent) provides a reliable baseline for comparison

Referral pathways in the UK are well-defined. Where malignancy is suspected, patients should be referred urgently via the two-week-wait breast clinic pathway under NICE NG12; imaging and biopsy are arranged by the specialist breast team as part of triple assessment. Nurses should not arrange mammography or ultrasound independently outside agreed local protocols. Where a testicular mass is identified or β-hCG is elevated, urgent urology referral should be initiated. Those with confirmed pathological causes should be referred to the relevant specialist — for example, endocrinology for hormonal disorders, hepatology for liver disease, or urology for testicular pathology.

Patients who have not responded to conservative management after three to six months, or who are experiencing significant psychological distress, should be referred to an endocrinologist or breast surgeon for further evaluation and consideration of pharmacological or surgical treatment. Nurses should ensure that referral letters contain comprehensive clinical information to facilitate timely specialist review.

Patients should be clearly advised to seek prompt medical attention if they notice rapid breast enlargement, a hard or irregular lump, blood-stained nipple discharge, or skin changes — symptoms that warrant urgent reassessment. Empowering patients with this knowledge supports early detection and improves clinical outcomes.

Frequently Asked Questions